Search
Lexeo Therapeutics Inc
LXEOAdd to Watchlist
4.690USD
+0.240+5.39%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
347.45MMarket Cap
LossP/E TTM
More Details of Lexeo Therapeutics Inc Company
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Lexeo Therapeutics Inc Info
Ticker SymbolLXEO
Company nameLexeo Therapeutics Inc
IPO dateNov 03, 2023
CEOTownsend (R. Nolan)
Number of employees72
Security typeOrdinary Share
Fiscal year-endNov 03
Address345 Park Avenue South
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10010
Phone12125479879
Websitehttps://www.lexeotx.com/
Ticker SymbolLXEO
IPO dateNov 03, 2023
CEOTownsend (R. Nolan)
Company Executives of Lexeo Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Louis Tamayo
Mr. Louis Tamayo
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
89.67K
+49.81%
Dr. Jose Manuel Otero, Ph.D.
Dr. Jose Manuel Otero, Ph.D.
Chief Technical Officer
Chief Technical Officer
72.59K
-1.79%
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
10.42K
-5.90%
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jenny R. Robertson, J.D.
Ms. Jenny R. Robertson, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Ms. Paula H. J. Cholmondeley
Ms. Paula H. J. Cholmondeley
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Louis Tamayo
Mr. Louis Tamayo
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
89.67K
+49.81%
Dr. Jose Manuel Otero, Ph.D.
Dr. Jose Manuel Otero, Ph.D.
Chief Technical Officer
Chief Technical Officer
72.59K
-1.79%
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
10.42K
-5.90%
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jenny R. Robertson, J.D.
Ms. Jenny R. Robertson, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
FAQs
Who are the top five shareholders of Lexeo Therapeutics Inc?
The top five shareholders of Lexeo Therapeutics Inc are: Mr. Louis Tamayo
How many institutions hold shares of Lexeo Therapeutics Inc (LXEO)?
As of 2026Q1, 253 institutions hold shares of Lexeo Therapeutics Inc, with a combined market value of approximately 88.41M, accounting for 112.72% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 15504752.00.